Please login to the form below

Santaris

This page shows the latest Santaris news and features for those working in and with pharma, biotech and healthcare.

Roche boosts respiratory presence with InterMune purchase

These include a $450m deal to acquire gene silencing specialist Santaris earlier this month, an offering of $1.7bn for cancer company Seragon in July and a $350m bargain for sequencing

Latest news

Chugai soars on Roche buyout rumours

Roche has been making targeted acquisitions of late – offering $450m for gene silencing company Santaris earlier this month, $1.7bn for cancer company Seragon Pharmaceuticals in July and $350m for sequencing
Roche pays $450m for 'gene-silencing' firm Santaris Pharma

Roche's return to the field of RNAi research looks to be complete, following its $450m deal to acquire Denmark's Santaris Pharma. ... The deal is expected to close later this month, when Santaris' Danish operations will become the Roche Innovation Center
Shire extends rare genetic disease alliance

Agrees option with Santaris to nominate additional discovery targets. Shire has expanded its rare genetic disease alliance with Danish biopharmaceutical company Santaris. ... The Danish clinical stage biopharmaceutical company's president and CEO Henrik
RNA interference rebirth

ALN-RSV01. Alnylam. RSV. respiratory syncytial virus infection. IIb. miravirsen (SPC3649). Santaris Pharma. ... I. EZN-3042. Santaris Pharma. Survivin. cancer. I. EZN-2968. Santaris Pharma. HIF-1a.
Creative partnerships

In January, Pfizer extended an existing collaboration with Santaris ($614m) for the 'locked nucleic acid' (LNA) technology for gene-silencing RNA technology. ... Preclinical. 632. Santaris Pharma/Pfizer. Expansion of Locked Nucleic Acid Drug platform

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for August 2014

587.5. Santaris/ Roche (pRED). Company acquisition. Locked Nucleic Acid (LNA) platform for RNA-targeting therapeutics.
Pharma deals during August 2014

August also saw Roche's pRED group acquire Santaris Pharma for $450m - $250m upfront and $200m contingent on predetermined research milestones. ... Clearly it has not taken Roche long to be convinced of these claims given its $10m discovery alliance with
Deal Watch table for January 2014

Santaris/Roche. Discovery and development. Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform.
Pharma deals during April 2013

Platform technologies. Of the 11 large pharma deals announced in April, 8 involve platform technologies. In addition to those already mentioned are: Ambrx / Astellas; Isis/ Roche; Ra/ Merck; Santaris/ Bristol-Myers ... Santaris/ BMS. April also saw
Deal Watch table for April 2013

199. Velcera/ Perrigo Company. Acquisition. Pet health products. 160. Santaris Pharma/ BMS.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Hansa Medical poaches Vifor Pharma’s CEO

Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in several senior commercial roles within Merck &Co and Sandoz Pharma.
Shire elects new chair

the recent purchase of Virophama and an alliance agreed last year with Santaris.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Senior External Communications Lead: £Competitive Salary

Account Director: £Competitive Salary

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Publications director: Competitive salary and bonus scheme

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Manager: £Competitive Salary

Senior Medical Writer, MedComms Agency: Salary TBC

Account director: Competitive salary and bonus scheme

Experienced medical editor: Competitive salary and bonus scheme

Account Manager (PR): Great Benefits

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Subscribe to our email news alerts

PMHub

Add my company

Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...